Get the Daily Brief
Latest Biotech News
BioCryst buys Astria for ~$700M — Adds long‑acting HAE injectable
BioCryst Pharmaceuticals agreed to acquire Astria Therapeutics in a cash‑and‑stock transaction valuing Astria at about $700 million, adding navenibart — a long‑acting plasma kallikrein inhibitor...
FDA delays Denali decision — PDUFA for Hunter syndrome drug pushed three months
The FDA extended its review of Denali Therapeutics’ biologics license application for tividenofusp (tivi), an enzyme‑replacement therapy for Hunter syndrome, moving the PDUFA date by three months....
In vivo immune programming expands — Create Medicines rebrands; Liberate Bio raises seed
Create Medicines (formerly Myeloid Therapeutics) announced a strategic expansion beyond myeloid programming to include in vivo mRNA‑LNP programming of T cells and NK cells, aiming for scalable,...
AI in drug discovery accelerates — Lila adds $115M, Benchling integrates Nvidia models
Lila Sciences expanded its Series A with an additional $115 million — including investment from Nvidia’s venture arm — bringing its total haul to $350 million to fund ambitions in AI‑driven...
Sequencing price wars heat up — PacBio adds reusable consumables; Ultima pushes Solaris throughput
Pacific Biosciences unveiled a program to allow select customers to wash and reuse SMRT cell consumables and launched a new Sprq‑Nx chemistry that increases output and adds 5‑hydroxymethylcytosine...
Single‑cell scale‑up: automation meets high‑resolution multi‑omics
SPT Labtech and 10x Genomics announced a strategic partnership to automate single‑cell workflows by combining SPT’s Firefly liquid‑handling platform with 10x’s Chromium single‑cell chemistry and...
Novo Nordisk buys Omeros PNH drug: $2.1 billion deal
Novo Nordisk agreed to acquire Omeros’ stalled MASP‑3 inhibitor program, paying up to $2.1 billion to pick up the paroxysmal nocturnal hemoglobinuria (PNH) candidate and related rights. The deal...
Biocryst buys Astria – $700M pick‑up for hereditary angioedema
Biocryst Pharmaceuticals agreed to acquire Astria Therapeutics for roughly $700 million in cash and stock to add Astria’s long‑acting injectable navenibart, a plasma kallikrein inhibitor in...
Tubulis raises $361M to expand ADC program – clinical push
German antibody‑drug conjugate (ADC) developer Tubulis closed a $361 million financing to accelerate clinical development of its lead ADC, TUB‑040, and expand testing into additional tumor types...
Kailera nets $600M to carry Zepbound‑style obesity shot into Phase 3
Kailera Therapeutics secured $600 million in a Series B round led by Bain Capital Private Equity to advance KAI‑9531, a weekly injectable that targets the same receptors as established GLP‑1/GIP...
Create Medicines rebrands – in vivo mRNA CARs target T and NK cells
Create Medicines (formerly Myeloid Therapeutics) announced a rebrand and an expanded development strategy to program multiple immune cell lineages in vivo using its mRNA‑LNP platform. The company...
PacBio cuts price per genome… and wins Korea pangenome contract
Pacific Biosciences unveiled a plan to allow selected customers to reuse its most expensive SMRT cell consumables and launched a new Sprq‑Nx chemistry that raises output and adds...
FDA clears two INDs: TRX‑319 for progressive MS and CVT‑130 for cardioprotection
Two IND clearances this week open clinical development in distinct therapeutic areas. Tr1x Inc. received FDA clearance for TRX‑319 to begin a phase I/IIa study in progressive multiple sclerosis,...
GoT‑Multi co‑maps leukemia evolution in FFPE samples – single‑cell leap
Researchers at Weill Cornell Medicine and the University of Adelaide released GoT‑Multi, a high‑throughput single‑cell multi‑omics method that co‑detects multiple somatic genotypes and whole...
Benchling integrates NVIDIA BioNeMo: protein structure and generative models in platform
Benchling announced integration of NVIDIA BioNeMo models and NIM microservices into its AI platform, initially enabling users to run OpenFold2 structure predictions inside Benchling and promising...
Tempus AI lands $60M ARPA‑H contract to power adaptive cancer biomarker trials
Tempus AI won a $60 million contract from ARPA‑H to provide testing and contract research services for a project that uses biomarkers to develop adaptive treatment strategies in cancer. The award...
Tubulis raises $361M — ADC data debut looms
Tubulis completed a large late-stage private financing to accelerate clinical programs for next-generation antibody-drug conjugates (ADCs). The Munich-based biotech secured roughly $360–361...
Kailera secures $600M — obesity shot heads to global Phase 3
Kailera Therapeutics closed a $600 million financing led by Bain Capital Private Equity to support global Phase 3 trials of KAI‑9531, a weekly injectable aimed at the same dual targets as Eli...
BioCryst buys Astria for $700M — adds long‑acting HAE injectible
BioCryst Pharmaceuticals agreed to acquire Astria Therapeutics in a cash-and-stock deal with about $700 million enterprise value to obtain Astria’s long‑acting injectable HAE candidate,...
FDA delays Denali decision — PDUFA extended three months
The FDA pushed back its review decision on Denali Therapeutics’ candidate for Hunter syndrome by three months after the company submitted updated clinical pharmacology information, which the...